The use of azepane as a scaffold for drug discovery remains of interest. The azepane linker is the key to efficient activity. A number of seven-membered ring derivatives have been prepared or investigated for their potential or actual pharmacological properties. Examples include azaalkane derivatives as PKB (protein kinase B) inhibitors.
DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells, by inhibiting the ULK1/2 kinases, which have been shown to be the initiating factors that activate autophagy. DCC-3116 in combination with RAS/MAP kinase signaling pathway inhibition has the potential to change the treatment of RAS/RAF cancers. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Search 
+86 21 5895 0110 
